A phase I/II study of hypofractionated whole abdominal radiation therapy in patients with chemoresistant ovarian carcinoma: Karnofsky score determines treatment outcome

被引:19
作者
Faul, G
Gerszten, K
Edwards, R
Land, S
D'Angelo, G
Kelley, J
Price, F
机构
[1] Magee Womens Hosp, Dept Radiat Oncol, Pittsburgh, PA 15213 USA
[2] Magee Womens Hosp, Dept Gynecol Oncol, Pittsburgh, PA 15213 USA
[3] Univ Pittsburgh, Pittsburgh Canc Inst, Biometry Grp, Pittsburgh, PA USA
来源
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2000年 / 47卷 / 03期
关键词
ovarian cancer; whole abdominal radiation; quality of life; Karnofsky scale;
D O I
10.1016/S0360-3016(00)00446-6
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: Radiation therapy can provide useful palliation in chemorefractory ovarian cancer patients. The purpose of this study was to prospectively study the palliative effect of a hypofractionated radiation treatment regimen, Change in quality-of-life scores (Functional Assessment of Cancer Therapy [FACT], Karnofsky scale), pain score, and tolerance to therapy were also assessed. Methods and Materials: A single-institution Phase I/II trial was initiated in patients with chemoresistant recurrent or progressive ovarian cancer. All patients had symptomatic and measurable intra-abdominal disease. Patients were treated with a single radiation fraction (700 cGy) or two fractions (300 cGy twice a day) to the whole abdomen over 1 day, Quality-of-life scale (FACT G version 2) was assessed at baseline and 1 and 3 months following treatment. Karnofsky scale and pain score were also evaluated in the same time frame. Results: Sixteen patients were prospectively entered into this protocol between February 1996 and September 1998. Twelve patients received a single 700 cGy fraction and four 300 cGy twice a day. All were heavily pretreated and 9 (56%) had a poor performance status prior to treatment. Symptoms needing palliation included pain (14), ascites (10), and bleeding (2), Symptomatic improvement occurred in all patients with pain (5 complete response [CR] and 7 partial response [PR], all patients with bleeding (CR 2), and two (20%) with ascites. Five patients (31%) had a reduction in lesion size documented radiologically in three, The mean duration of response was 22 weeks in patients with a Karnofsky score >70, Thirteen patients developed transient nausea and vomiting which resolved in 48 hours in all. All patients developed a transient lymphopenia. Thirteen patients completed a follow-up quality-of-life scale. There was an improvement in the physical and functional components of the scale in patients with Karnofsky score of 90-100, There was no improvement in quality of life in patients with Karnofsky score <90 despite symptomatic response, Median survival was 3 months from the date of treatment. Conclusion: Hypofractionated radiation therapy is an effective palliative treatment for end-stage ovarian cancer patients, Karnofsky score can help determine the duration of response and survival for this high-risk population. (C) 2000 Elsevier Science Inc.
引用
收藏
页码:749 / 754
页数:6
相关论文
共 22 条
[11]  
JONG P, 1995, CAN J SURG, V38, P454
[12]  
Kavanagh JJ, 1996, CLIN CANCER RES, V2, P837
[13]  
KORNBLITH AB, 1995, GYNECOL ONCOL, V59, P231
[14]  
MARKMAN M, 1995, SEMIN ONCOL, V22, P25
[15]   PALLIATIVE BENEFIT OF RADIATION-THERAPY IN ADVANCED OVARIAN-CANCER [J].
MAY, LF ;
BELINSON, JL ;
ROLAND, TA .
GYNECOLOGIC ONCOLOGY, 1990, 37 (03) :408-411
[16]   Quality of life in patients with ovarian cancer: Current state of research [J].
Montazeri, A ;
McEwen, J ;
Gillis, CR .
SUPPORTIVE CARE IN CANCER, 1996, 4 (03) :169-179
[17]  
Munstedt K, 1995, Eur J Gynaecol Oncol, V16, P174
[18]   Ovarian cancer - Current outlook on this deadly disease [J].
Nahhas, WA .
POSTGRADUATE MEDICINE, 1997, 102 (03) :112-&
[19]   THE INTERRELATIONSHIP OF WEIGHT-LOSS, DIETARY-INTAKE, AND QUALITY-OF-LIFE IN AMBULATORY PATIENTS WITH CANCER OF THE LUNG, BREAST, AND OVARY [J].
OVESEN, L ;
HANNIBAL, J ;
MORTENSEN, EL .
NUTRITION AND CANCER-AN INTERNATIONAL JOURNAL, 1993, 19 (02) :159-167
[20]  
PORTENOY RK, 1994, CANCER-AM CANCER SOC, V74, P907, DOI 10.1002/1097-0142(19940801)74:3<907::AID-CNCR2820740318>3.0.CO